MCL treatment choices depend partly on ageOctober 10, 2018Mantle Cell LymphomaAggressive LymphomasB Cell Lymphoma
FDA lifts partial hold on tazemetostat trialsSeptember 30, 2018T Cell LymphomasAggressive LymphomasB Cell Lymphoma
Prognostic factors guide mantle cell treatment decisionsSeptember 28, 2018Mantle Cell LymphomaAggressive LymphomasB Cell Lymphoma
CAR T-cell studies dominate ongoing cellular therapy trialsSeptember 26, 2018Cellular TherapyAggressive LymphomasB Cell Lymphoma
Outpatient lenalidomide/rituximab yields long-term MCL remissionSeptember 25, 2018Mantle Cell LymphomaAggressive LymphomasB Cell Lymphoma
NICE looks likely to reject use of Kymriah for DLBCLSeptember 24, 2018Cellular TherapyBusiness of MedicineAggressive LymphomasB Cell Lymphoma
Kymriah cost effectiveness depends on long-term outcomesSeptember 17, 2018ALLBusiness of MedicineCellular TherapyB Cell Lymphoma
Pruritus linked to wide variety of cancersSeptember 16, 2018Indolent LymphomaAMLB Cell LymphomaB Cell Lymphoma
TP53 mutation plus complex karyotype equals poor prognosisSeptember 10, 2018Mantle Cell LymphomaAggressive LymphomasB Cell Lymphoma
ASCO updates guidance on prophylaxis for adults with cancer-related immunosuppressionSeptember 7, 2018Patient & Survivor CareIndolent LymphomaB Cell Lymphoma